There are currently 85 active clinical trials seeking participants for Cervical Cancer research studies. The states with the highest number of trials for Cervical Cancer participants are California, Texas, Ohio and New York.
Detecting HPV DNA in Anal and Cervical Cancers
NCT04857528
Recruiting
This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood of study participants before, during, and after radiation treatment. They will also collect blood and archival tumor tissue (from a previous biopsy) to perform other tests in the future that could provide more info... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/26/2024
Locations: University of Illinois at Chicago, Chicago, Illinois +1 locations
Conditions: Cervical Cancer, Anal Cancer, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, Uterine Cervical Cancer
Register for Updates
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
NCT05512208
Recruiting
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or cervical cancer.
Gender:
Female
Ages:
Between 18 years and 99 years
Trial Updated:
01/26/2024
Locations: University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico +1 locations
Conditions: Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer, Cervical Cancer, Solid Tumor
Register for Updates
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
NCT05563272
Recruiting
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
01/24/2024
Locations: Biogenix Molecular, LLC, Miami, Florida +4 locations
Conditions: Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma
Register for Updates
PEER Trial: Part 2 Rice Technologies
NCT05372484
Recruiting
The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.
Gender:
Female
Ages:
Between 25 years and 49 years
Trial Updated:
01/23/2024
Locations: M D Anderson Cancer Center, Houston, Texas +3 locations
Conditions: Cervical Cancer
Register for Updates
Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors
NCT05098132
Recruiting
This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: UC San Diego Moores Cancer Center, La Jolla, California +12 locations
Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
Register for Updates
Cervical Cancer Detection Using Optical Spectroscopy
NCT00900575
Recruiting
The objective of the work described in this protocol is to determine the optical signatures of cervical dysplasia using optical technologies.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Cervical Cancer
Register for Updates
Pilot Study for Speculum Free Cervical Cancer Screening
NCT04107181
Recruiting
The objective of the work described in this protocol is to determine the optical signatures of cervical dysplasia using optical technologies.
Gender:
Female
Ages:
Between 21 years and 65 years
Trial Updated:
01/08/2024
Locations: Duke University, Durham, North Carolina
Conditions: Cervical Cancer
Register for Updates
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
NCT06128304
Recruiting
While there has been a significant increase in the uptake of antiretroviral therapy among women living with HIV (WLHIV) in many low- and-middle income countries (LMICs), the coverage of cervical cancer screening and treatment (CCST) among WLHIV remains low. This study aims to leverage the available infrastructure for HIV care and treatment programs in Nigeria to integrate cervical cancer screening and treatment and conduct a cluster randomized, hybrid type III trial design to assess the comparat... Read More
Gender:
Female
Ages:
Between 25 years and 65 years
Trial Updated:
12/29/2023
Locations: UC San Diego, La Jolla, California +1 locations
Conditions: HIV, Cervical Cancer
Register for Updates
Whole Pelvis Proton Radiation for Gynecologic Cancer
NCT05758688
Recruiting
This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-surgical, adjuvant setting for definitive treatment of gynecologic cancers. The purpose of this study is to estimate rate of acute clinician-reported gastrointestinal (GI) toxicity using WP PBS PRT in the definitive treatment of gynecologic cancers in the post-surgical, adjuvant setting.
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/19/2023
Locations: Penn Medicine, Philadelphia, Pennsylvania
Conditions: Cervical Cancer, Uterine Cancer
Register for Updates
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT05483491
Recruiting
This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to treatment will be determined.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/07/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
Register for Updates
Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2
NCT06082882
Recruiting
The purpose of this study is to increase early detection and prevention of breast and cervical cancer through education and navigation and to increase breast and cervical cancer screening and Human Papillomavirus (HPV) vaccination in underserved Latinas.
Gender:
Female
Ages:
Between 18 years and 74 years
Trial Updated:
11/27/2023
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Breast Cancer, Cervical Cancer
Register for Updates
The Registry of Oncology Outcomes Associated With Testing and Treatment
NCT04028479
Recruiting
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and retrospective in nature.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/20/2023
Locations: Teton Cancer Institute, Idaho Falls, Idaho +1 locations
Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Register for Updates